Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.

Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW.

Science. 2008 Sep 26;321(5897):1801-6. doi: 10.1126/science.1164368. Epub 2008 Sep 4.

2.

Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.

Witkiewicz A, Williams TK, Cozzitorto J, Durkan B, Showalter SL, Yeo CJ, Brody JR.

J Am Coll Surg. 2008 May;206(5):849-54; discussion 854-6. doi: 10.1016/j.jamcollsurg.2007.12.014. Epub 2008 Mar 4.

PMID:
18471709
3.

Immune escape as a fundamental trait of cancer: focus on IDO.

Prendergast GC.

Oncogene. 2008 Jun 26;27(28):3889-900. doi: 10.1038/onc.2008.35. Epub 2008 Mar 3. Review.

PMID:
18317452
4.

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.

Colombo MP, Piconese S.

Nat Rev Cancer. 2007 Nov;7(11):880-7. Review.

PMID:
17957190
5.

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.

Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC.

Cancer Res. 2007 Aug 1;67(15):7082-7.

6.

Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Munn DH, Mellor AL.

J Clin Invest. 2007 May;117(5):1147-54. Review.

7.

Indoleamine 2,3-dioxygenase in immune suppression and cancer.

Muller AJ, Prendergast GC.

Curr Cancer Drug Targets. 2007 Feb;7(1):31-40. Review.

PMID:
17305476
8.

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH.

Cancer Res. 2007 Jan 15;67(2):792-801.

9.

The case for routine use of adjuvant therapy in pancreatic cancer.

Kennedy EP, Yeo CJ.

J Surg Oncol. 2007 Jun 1;95(7):597-603. Review.

PMID:
17230543
10.

1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD, Yeo CJ.

J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1.

PMID:
17114007
11.

Cancer despite immunosurveillance: immunoselection and immunosubversion.

Zitvogel L, Tesniere A, Kroemer G.

Nat Rev Immunol. 2006 Oct;6(10):715-27. Epub 2006 Sep 15. Review.

PMID:
16977338
12.

Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.

Calhoun ES, Hucl T, Gallmeier E, West KM, Arking DE, Maitra A, Iacobuzio-Donahue CA, Chakravarti A, Hruban RH, Kern SE.

Cancer Res. 2006 Aug 15;66(16):7920-8.

13.

The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.

Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P.

J Immunol. 2006 Jun 1;176(11):6752-61.

14.

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Göbel G, Margreiter R, Königsrainer A, Fuchs D, Amberger A.

Clin Cancer Res. 2006 Feb 15;12(4):1144-51.

15.

Marrying immunotherapy with chemotherapy: why say IDO?

Muller AJ, Prendergast GC.

Cancer Res. 2005 Sep 15;65(18):8065-8. Review.

16.

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.

Muller AJ, Malachowski WP, Prendergast GC.

Expert Opin Ther Targets. 2005 Aug;9(4):831-49. Review.

PMID:
16083346
17.

Immunotherapy for pancreatic cancer - science driving clinical progress.

Laheru D, Jaffee EM.

Nat Rev Cancer. 2005 Jun;5(6):459-67. Review.

PMID:
15905855
18.

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC.

Nat Med. 2005 Mar;11(3):312-9. Epub 2005 Feb 13.

PMID:
15711557
19.

Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media.

Brody JR, Calhoun ES, Gallmeier E, Creavalle TD, Kern SE.

Biotechniques. 2004 Oct;37(4):598, 600, 602.

PMID:
15517972
20.

Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss.

Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR, Troup WJ, Romm JM, Doheny K, Pugh E, Yeo CJ, Goggins MG, Hruban RH, Kern SE.

Cancer Res. 2004 Feb 1;64(3):871-5.

Supplemental Content

Support Center